Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
Tarsus Pharmaceuticals reported strong fourth quarter and full-year 2025 growth driven by its Demodex blepharitis eye drop XDEMVY. Full-year 2025 net product sales of XDEMVY reached $451.4 million, an increase of more than 150% year-over-year, with fourth quarter net product sales of $151.7 million.
The company delivered about 400,000 bottles to patients in 2025 and maintained gross margins of 93%. Despite heavy investment in commercial and R&D spend, the full-year net loss narrowed to $66.4 million from $115.6 million, with basic and diluted loss per share improving to $(1.59) from $(3.07).
Tarsus ended 2025 with a strong cash position of $417.3 million in cash, cash equivalents and marketable securities. Management highlighted peak sales potential for XDEMVY of more than $2 billion and ongoing Phase 2 development for TP-04 in ocular rosacea and TP-05 for Lyme disease prevention.
PYOTT DAVID E I reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director David E. I. Pyott received new equity awards. On February 18, 2026, he was granted 5,893 stock options with a right to buy Tarsus common stock and 3,729 restricted stock units (RSUs).
The option grant will vest in three equal annual installments on February 18 of 2027, 2028, and 2029, contingent on his continuous service. Each RSU represents one share of common stock and will vest in three equal annual installments on March 15 of 2027, 2028, and 2029, also subject to continued service.
Tarsus Pharmaceuticals director David E. I. Pyott filed an initial statement of beneficial ownership, reporting his equity holdings in the company. The filing lists several stock options granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan that vested and became exercisable on April 24, 2023, August 1, 2024, and April 24, 2025. Another option grant is scheduled to vest and become exercisable on April 24, 2026, subject to his continuous service. He also holds restricted stock units that vest on April 24, 2026, subject to continuous service. In addition, 7,991 shares of common stock are reported as held indirectly by the David E.I. Pyott Trust.
Tarsus Pharmaceuticals, Inc. has expanded its Board of Directors from seven to eight members and appointed David E.I. Pyott, former Chairman and CEO of Allergan, as a Class III director effective immediately. His term runs until the 2026 annual meeting of stockholders, or until a successor is elected and qualified.
Pyott will serve as Chairperson of the Board’s Commercial Committee and as a member of the Nominating and Corporate Governance and Compensation Committees. He is classified as an independent director under Nasdaq and SEC rules and will receive cash and equity compensation under Tarsus’ non-employee director compensation policy, including an initial equity grant with a target value of
Tarsus Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that investment entities associated with Kevin Tang collectively beneficially own 1,188,624 shares of Tarsus common stock. This represents 2.80% of the company’s outstanding common shares as of October 29, 2025.
The shares are held with shared voting and dispositive power through Tang Capital Management, LLC and its affiliated funds, including Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. The filing notes that the securities are not held for the purpose of changing or influencing control of Tarsus.
Tarsus Pharmaceuticals, Inc. director Katherine Goodrich reported the settlement of vested restricted stock units into common shares. On December 15, 2025, 2,233 restricted stock units (RSUs) were converted into 2,233 shares of common stock at a reported price of $0.00 per share, which she now holds directly.
Following this transaction, Goodrich directly holds 2,233 common shares and 4,467 RSUs. The RSUs are scheduled to vest in three equal installments on December 15 of 2025, 2026 and 2027, subject to her continuous service with the company, with each RSU representing the right to receive one share of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. furnished a new corporate presentation under Regulation FD. The company posted the presentation on the Investor & News section of its website and attached it as Exhibit 99.1 to this report. The materials are designated as “furnished” rather than “filed,” which means they are not subject to certain liability provisions under the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless expressly stated.
Tarsus Pharmaceuticals’ Chief Human Resources Officer, Dianne C. Whitfield, reported automatic stock sales made under a pre-arranged Rule 10b5-1 trading plan. On January 2, 2026, she sold a total of 15,565 shares of Tarsus common stock in four transactions at weighted average prices ranging from about $80.09 to $82.93. The footnotes explain that each reported price is a weighted average for multiple individual trades, with actual prices spanning from $79.42 to $83.32. After these sales, she directly owned 23,393 shares of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer reported stock gifts in an insider filing. On 12/16/2025, he transferred 950 shares of common stock at a stated price of $0, leaving 79,183 shares of common stock held directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025.
A separate reported transaction on the same date reflects a gift coded as G(2) involving 475 shares of common stock held indirectly by his daughter. The report notes that he disclaims beneficial ownership of the securities held by his daughter and that this reporting is not an admission of beneficial ownership for Section 16 or any other purpose.
Tarsus Pharmaceuticals, Inc. disclosed that its Chief Human Resources Officer, an officer of the company, sold common stock in a pre‑planned trade. On 12/16/2025, the officer sold 7,397 shares of Tarsus common stock at a price of $80.1 per share in a transaction coded as a sale. The filing states that this was an automatic sale made under a Rule 10b5‑1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance. After this transaction, the officer beneficially owned 38,958 shares of Tarsus common stock, held directly.